NCT06588296 (TOGETHER-PsA) (80) is a Phase 3b, randomized, multicentre, open-label study examining the efficacy and safety of ixekizumab compared to ixekizumab concomitantly administered with tirzepatide in overweight or obese adult patients with active PsA and at least one weight-related comorbidity
Insurance approval depends on specific plan designs, prior authorization requirements, and documented medical necessity
Severe nausea, vomiting, gastroparesis, and pancreatitis are all documented concerns with aggressive semaglutide escalation
When to Seek Medical Advice About Headaches Whilst most headaches associated with Ozempic are benign and self-limiting, certain features warrant prompt medical assessment
Owner and holistic nutritionist Robin Hutchinson is here to help you succeed with or without these new weight loss drugs
Lemonbottle products contain bromelain that is derived from pineapples, and injection can have unpredictable effects